Could your own tumor cells fight cancer? new trial tests TIL therapy

NCT ID NCT06488950

Recruiting now Disease control Sponsor: Shanghai Juncell Therapeutics Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase trial tests a personalized therapy where immune cells (TILs) are taken from a patient's own tumor, multiplied in a lab, and infused back into the body to attack the cancer. The study includes both natural and gene-edited TILs and enrolls 30 adults with advanced solid tumors who have exhausted standard treatments. The main goal is to check safety, with early signs of tumor shrinkage also being measured.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: tumor-infiltrating lymphocytes (TILs) - either natural or gene-edited
What this could lead to: If successful, this could point toward a new treatment option for advanced solid tumors that have not responded to standard therapies.
What could go wrong: This is a very early, small trial (30 people) focused on safety, so it may not show strong anti-tumor effects. Side effects from the lymphodepletion and TIL infusion could be significant.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED SOLID TUMOR EFFECTS OF IMMUNOTHERAPY TREATMENT SIDE EFFECTS TUMOR INFILTRATING LYMPHOCYTES

Contacts and locations

Locations

Third Affiliated Hospital of Naval Medical University
RECRUITING

Shanghai, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.